Literature DB >> 27063442

Single 3-Minute versus Double 4-Minute Freeze Strategy for Second-Generation Cryoballoon Ablation: A Single-Center Experience.

Giuseppe Ciconte1, Juan Sieira-Moret1, Ebru Hacioglu1, Giacomo Mugnai1, Giacomo DI Giovanni1, Vedran Velagic1, Yukio Saitoh1, Giulio Conte1, Ghazala Irfan1, Giannis Baltogiannis1, Burak Hunuk1, Erwin Stroker1, Pedro Brugada1, Carlo DE Asmundis1, Gian-Battista Chierchia1.   

Abstract

INTRODUCTION: Second-generation cryoballoon (CB-Adv) ablation is highly effective in achieving pulmonary vein isolation (PVI) with promising mid-term clinical outcome. However, the ideal freezing strategy is still under debate. The aim of this study was to assess the efficacy of a single 3-minute approach compared to the conventional 4-minute plus bonus application using CB-Adv. METHODS AND
RESULTS: One hundred and sixty patients (67% male; mean age 58.0 ± 13.3 years) underwent PVI using CB-Adv for paroxysmal atrial fibrillation (PAF). Among 160 patients, 80 received a single 3-minute approach (3-mns group), while the remaining 80 conventional 4-minute plus bonus-freeze (4-mns group). Mean procedure and fluoroscopy times were 90.6 ± 15.8 and 18.3 ± 6.9 in the 4-mns group, 75.2 ± 17.1 and 13.5 ± 8.7 in the 3-mns group (P < 0.001, respectively). First-freeze isolation rate was 91.6% in the 4- versus 90.6% in the 3-mns group (P = 0.78). Persistent phrenic nerve palsy (PNP) occurred in 6/80 (3.5%) in the 4-mns group and 4/80 in the 3-mns group (P = 0.75). The overall freedom from ATas 2 years after the procedure was 78.1% (125/160): 77.5% (62/80 patients) in the 3-mns and 78.8% (63/80 patients) in the 4-mns group (P = 0.82). In multivariate analysis, time to PVI and nadir temperature independently predicted ATa recurrences (P < 0.001).
CONCLUSIONS: CB-Adv ablation for PAF is highly effective, resulting in 78% 2-year freedom from arrhythmic recurrences. A "single 3-minute strategy" showed equal efficacy as compared to the conventional 4-minute plus bonus freeze approach at 2-year follow-up, providing shorter procedure and fluoroscopy time. Nadir temperature and time to PVI were predictors of arrhythmic recurrences. "Bonus-freeze" strategy might be unnecessary.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cryoballoon ablation; paroxysmal atrial fibrillation; phrenic nerve injury; pulmonary vein isolation; second-generation cryoballoon; single freeze

Mesh:

Year:  2016        PMID: 27063442     DOI: 10.1111/jce.12986

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  10 in total

1.  Temperature-guided ablation with the second-generation cryoballoon for paroxysmal atrial fibrillation: 3-year follow-up in a multicenter experience.

Authors:  Gaetano Paparella; Saverio Iacopino; Thiago Guimarães Osório; Juan Pablo Abugattas de Torres; Erwin Ströker; Juan Sieira; Hannes Vanacker; Bernard De Ruyter; Serge Boveda; Riccardo Maj; Gianluca Borio; Alessandro Rizzo; Alessio Galli; Pedro Brugada; Carlo de Asmundis; Gian-Battista Chierchia
Journal:  J Interv Card Electrophysiol       Date:  2020-05-31       Impact factor: 1.900

2.  Ablation of atrial fibrillation: single-shot techniques poised to dominate rhythm control strategies/the future is here.

Authors:  Antonis S Manolis
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

3.  New individualized strategy instructs cryoballoon energy ablation.

Authors:  Wei-Dong Lin; Xian-Hong Fang; Yu-Mei Xue; Hong-Tao Liao
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 4.  The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications.

Authors:  Fehmi Keçe; Katja Zeppenfeld; Serge A Trines
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

Review 5.  Cryoballoon ablation of atrial fibrillation: a practical and effective approach.

Authors:  George Georgiopoulos; Dimitris Tsiachris; Antonis S Manolis
Journal:  Clin Cardiol       Date:  2016-12-19       Impact factor: 2.882

6.  Effect of pulmonary vein cryoballoon ablation in dogs with coolant-nitrogen.

Authors:  Yun Xie; Rong Guo; Meiyu Yan; Tingting Zhao; Yawei Xu; Dongdong Zhao
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

7.  Long-term outcome after second-generation cryoballoon ablation for paroxysmal atrial fibrillation - a 3-years follow-up.

Authors:  Ken Takarada; Ingrid Overeinder; Carlo de Asmundis; Erwin Stroker; Giacomo Mugnai; Valentina de Regibus; Darragh Moran; Hugo Coutino-Moreno; Juan-Pablo Abugattas; Rajin Choudhury; Diego Ruggiero; Gaetano Paparella; Saverio Iacopino; Pedro Brugada; Gian-Battista Chierchia
Journal:  J Interv Card Electrophysiol       Date:  2017-03-10       Impact factor: 1.900

8.  Single freeze strategy with the second- generation cryballoon for atrial fibrillation: a multicenter international retrospective analysis in a large cohort of patients.

Authors:  Valentina De Regibus; Saverio Iacopino; Juan Pablo Abugattas; Hugo Enrique Coutiño; Giacomo Mugnai; Cesare Storti; Giulio Conte; Angelo Auricchio; Darragh Moran; Erwin Ströker; Luis Marroquin; Ken Takarada; Rajin Choudhury; Carlo de Asmundis; Pedro Brugada; Gian-Battista Chierchia
Journal:  J Interv Card Electrophysiol       Date:  2017-06-01       Impact factor: 1.900

9.  Optimizing ablation duration using dormant conduction to reveal incomplete isolation with the second generation cryoballoon: A randomized controlled trial.

Authors:  Fehmi Keçe; Marta de Riva; Yoshihisa Naruse; Reza Alizadeh Dehnavi; Adrianus P Wijnmaalen; Martin J Schalij; Katja Zeppenfeld; Serge A Trines
Journal:  J Cardiovasc Electrophysiol       Date:  2019-03-29

10.  Randomised clinical trial of cryoballoon versus irrigated radio frequency catheter ablation for atrial fibrillation-the effect of double short versus standard exposure cryoablation duration during pulmonary vein isolation (CIRCA-DOSE): methods and rationale.

Authors:  Jason G Andrade; Marc W Deyell; Mariano Badra; Jean Champagne; Marc Dubuc; Peter Leong-Sit; Laurent Macle; Paul Novak; Jean-Francois Roux; John Sapp; Anthony Tang; Atul Verma; George A Wells; Paul Khairy
Journal:  BMJ Open       Date:  2017-10-05       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.